<DOC>
	<DOCNO>NCT02925494</DOCNO>
	<brief_summary>This extension study woman already receive six month treatment phase III clinical trial M12-815 M12-817 , evaluate long-term efficacy safety elagolix administer alone combination estradiol/norethindrone acetate additional six month treatment heavy menstrual bleeding associate uterine fibroid .</brief_summary>
	<brief_title>An Extension Study Evaluate Efficacy Safety Elagolix Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Participant complete 6Month Treatment Period respective Pivotal Study ( either Study M12815 Study M12817 ) . Participant meet removal criterion bone mineral density ( BMD ) decrease spine , total hip femoral neck Month 6 Treatment Period respective Pivotal Study Participant negative urine and/or serum pregnancy test ( ) result consistently negative Treatment Period respective Pivotal Study prior first dose study . Participant 's endometrial biopsy Month 6 Visit respective Pivotal Study show clinically significant endometrial pathology . Participant meet criterion removal therapy respective Pivotal Study . Participant planning pregnancy within next 18 month . Participant current suicidal marker note Month 6 visit respective pivotal study . Participant new medical condition may unsuitable participation . Participant use systemic corticosteroid 14 day likely require treatment systemic corticosteroid course study . Overthecounter prescription topical , inhale , intranasal injectable ( occasional use ) corticosteroid allow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Elagolix</keyword>
	<keyword>Elagolix plus Norethindrone Acetate</keyword>
	<keyword>Uterine Fibroids</keyword>
	<keyword>Elagolix Sodium</keyword>
	<keyword>Heavy Menstrual Bleeding</keyword>
</DOC>